Pharmacologic therapies for obesity.
This article examines the transitions in pharmacological therapy for obesity. It reviews the current options approved by the Food and Drug Administration and several drugs approved for other indications that can be used to treat obesity as well. Because weight regulation is complex and redundant systems protect against perceived starvation, optimal treatment of obesity in individual patients will likely require different combinations of behavioral, nutritional, pharmacologic, endoscopic, and surgical therapies.
Kaplan
Lee M
LM
MGH Weight Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, 50 Staniford Street, Boston, MA 02114, USA. LMKaplan@partners.org
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D050110:Bariatric Surgery; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use; D016642:Bupropion / Q000494:pharmacology / Q000627:therapeutic use; D003503:Cyclobutanes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004809:Ephedrine / Q000494:pharmacology / Q000627:therapeutic use; D005277:Fenfluramine / Q000009:adverse effects; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009271:Naltrexone / Q000494:pharmacology / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D010645:Phentermine / Q000494:pharmacology / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects; D015431:Weight Loss
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D001552:Benzazepines; D003503:Cyclobutanes; D007783:Lactones; D016642:Bupropion; D005277:Fenfluramine; D009271:Naltrexone; C506658:lorcaserin; D000077403:Orlistat; D010645:Phentermine; D004809:Ephedrine; C058254:sibutramine